Abstract

Question: Should Janssen COVID-19 vaccine be recommended for persons 18 years of age and older in the U.S. under an Emergency Use Authorization?

Population: Persons 18 years of age and older

Intervention: Janssen COVID-19 vaccine (5 × 1010 viral particles, single 0.5 ml dose IM)

Comparison: No COVID-19 vaccine

Outcomes:

  • Symptomatic laboratory-confirmed COVID-19
  • Hospitalization due to COVID-19
  • All-cause death
  • SARS-CoV-2 seroconversion to a non-spike protein
  • Asymptomatic SARS-CoV-2 infection
  • Serious adverse events
  • Reactogenicity grade ≥3
  • Background paper
  • Americas
  • United States of America
  • Janssen COVID-19 Vaccine
  • EtR framework
  • COVID-19